Fapon Biopharma

Focus: Fapon Biopharma is a China-based biologics and immunotherapy company focused on oncology and infectious disease treatment. The company operates as a clinical-stage biotech with early-phase pipeline programs.

Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Fapon Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Fapon Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

blood sampling

Adult Patients at High Risk of Sepsis

N/A

Clinical Trials (1)

NCT07232784Serial Measurement of Pancreatic Stone Protein (PSP) for Sepsis Early Detection in ICU Patients

N/A

Help build intelligence for Fapon Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to cutting-edge modalities: CAR-T cell therapy and novel immunotherapy approaches in high-unmet-need oncology indications
Ground-floor opportunity at an emerging biopharma in the high-growth Chinese biotech ecosystem
Potential to shape early-stage drug development in pancreatic cancer and advanced solid tumors with clinical programs in Phase 1

Watch Out For

Zero active job postings signal minimal hiring or potential organizational challenges
All pipeline programs remain in Phase 1 with no Phase 2+ readouts—high clinical attrition risk and extended timeline to revenue
No disclosed funding, financials, or employee count raises transparency and stability concerns
No published research output (0 publications) limits evidence of scientific rigor or institutional credibility

Generated by Claude from Fapon Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FP002 Injection

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05982080A Study to Investigate FP002 in Subjects With Advanced Malignancies

Phase 1

FP008 for injection

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06990698A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

Phase 1